Become A Featured Company

CB Therapeutics Closes on Oversubscribed Series A

Ryan Allway

May 10th, 2021

Psychedelics

  • CB Therapeutics raises Series A round with re.Mind Capital and accelerates its manufacturing and research of cannabinoids, tryptamines, and other therapeutics.
  • Christian Angermayer joins as Advisor; the board of directors expands with additions of Dr. Srinivas Rao, CSO of Atai Life Sciences; Dr. Jeff Miller, CEO of Invivoscribe; and Jan Hardorp, Founding Partner at re.Mind Capital.
  • CB Therapeutics is building the largest collection of biosynthetic tryptamines, cannabinoids, and their analogs, the PsyVault™.

 

 

SAN DIEGO–(BUSINESS WIRE May 10, 2021) –CB Therapeutics Inc., the leading synthetic biology company focused on the development and biosynthetic production of existing and novel tryptamines and cannabinoids, is pleased to announce that it has closed an oversubscribed Series A funding round, filled entirely by re.Mind Capital, a fund launched by the psychedelics kingmaker, Christian Angermayer within Apeiron, his family office.

 

CB Therapeutics develops synthetic biology solutions to address mental health issues and increase healthspan. Its proprietary cellular agriculture platform enables next generation biosynthetic production of cannabinoids and psychedelic medicines and their analogs to further clinical research for various serious health conditions. The natural synergy between re.Mind Capital, a group which funds impactful companies developing solutions for the global mental health crisis, and CB Therapeutics, will lead to breakthroughs in innovating and supplying therapeutic molecules to the nutraceutical market and clinical researchers.

 

In addition to the closing of its Series A, CB Therapeutics welcomes Christian Angermeyer as Advisor, along with three new members to its board of directors, which now consists of Dr. Srinivas Rao, CSO of Atai Life Sciences; Dr. Jeff Miller, CEO of Invivoscribe; Jan Hardorp, Founding Partner at re.Mind Capital; and the founders of CB Therapeutics, Sher Ali Butt, CEO, and Dr. Jacob Vogan, CSO. The expanded board and the members’ decades of biotech and clinical expertise will enable CB Therapeutics to excel and innovate in competitive global biotechnology and mental health markets.

 

“Words can’t express how excited we are to work alongside Christian, Apeiron, re.Mind, and the extended family of companies, as we believe this is hands-down the best group of investors and partners to work with in this industry,” said Sher Ali Butt, CEO of CB Therapeutics. “In fact, even more than the funding itself, the most exciting bits are working with Christian as our new Advisor, the re.Mind Capital team, and our awesome new board of directors. With this new funding, advisors, and the board, we aim to be the leading biotechnology company for the biosynthesis of tryptamines, cannabinoids, and their analogs.”

 

“This fresh round of funding for CB Therapeutics will allow us to rapidly accelerate our scaled up manufacturing and sale of cannabinoids and tryptamines,” said Dr. Jacob Vogan, CSO of CB Therapeutics. “We’re also very excited to have re.Mind Capital backing us as we expand our PsyVault™, the largest collection of biosynthetic cannabinoids, tryptamines, and other psychedelic molecules which have fantastic therapeutic potential.”

 

 

About CB Therapeutics

CB Therapeutics, Inc., located in San Diego, California, is a leading biotechnology companyfocusing on the innovative production of tryptamines, cannabinoids, and their analogs. CB Therapeutics’ expertise in synthetic genomics, bio-engineering and cellular production processes can produce a broad range of phytochemicals faster, more sustainably, at greater yields and with higher purity, consistency and efficiency than competitive platforms. The CB Therapeutics platform can not only make the active compounds and phytochemicals that occur naturally, but by using enzymatic processes CB Therapeutics has been able to create bio-identical compounds as well as their analogs. These analog compounds may prove to be more effective, targeted and safer for therapeutic purposes.

 

 

About re.Mind Capital

re.Mind Capital is the mental health VC arm of serial entrepreneur and investor Christian Angermayer and his family office Apeiron Investment Group. We seek out companies with innovative and highly impactful solutions to our global mental health crisis.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading